COMMUNIQUÉS West-GlobeNewswire

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

04/09/2024 - 22:05

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular [...]

QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease

04/09/2024 - 22:05

QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s [...]

Bolt Biotherapeutics Announces Changes to its Board of Directors

04/09/2024 - 22:05

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the [...]

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

04/09/2024 - 22:05

CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 22:05

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/09/2024 - 22:05

CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

04/09/2024 - 22:05

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer [...]

NeuroPace Strengthens Management Team with Two Key Appointments

04/09/2024 - 22:05

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific’s DBS franchise as the new Vice President of Marketing [...]

scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 22:05

BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery [...]

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 22:05

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic [...]

Spero Therapeutics to Present at Upcoming September Investor Conferences

04/09/2024 - 22:05

CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing [...]

Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference

04/09/2024 - 22:01

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will [...]

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

04/09/2024 - 22:01

Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% [...]

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/09/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it granted stock options to purchase an aggregate of 51,039 shares of [...]

Safety Shot President Jordan Schur Invests an Additional $3.4 Million in the Company Through His Family Fund, Core 4 Capital Corp.

04/09/2024 - 20:00

JUPITER, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”) is pleased to announce that Safety Shot President Jordan Schur has invested in a $3.4 million private [...]

Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04/09/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Ipsen - Août 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

04/09/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

VALNEVA - Declaration of shares and voting rights: August 31, 2024

04/09/2024 - 18:00

VALNEVA Declaration of shares and voting rights August 31, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]

VALNEVA - Déclaration d’actions et de droits de vote : 31 août 2024

04/09/2024 - 18:00

VALNEVA Déclaration d’actions et de droits de vote 31 août 2024 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]